Use of electronic pill boxes to assess risk of poor treatment compliance: Results of a large-scale trial

American Journal of Hypertension

Volumn 12, Issue 4 I, 1999, Pages 374-380

  Vaur, Laurent ^a,e   Vaisse, Bernard ^b   Genes, Nathalie ^a   Elkik, François ^c   Legrand, Catherine ^d   Poggi, Louis ^b  

^a Medical Department   (France)

^b TIMONE HOSPITAL   (France)

^c SANOFI   (France)

^d Société Innovex   (France)

^e Laboratoires Roussel   (France)

Author keywords

Angiotensin converting enzyme inhibitor; Compliance; Electronic pill box; Risk factors

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANDOLAPRIL;

ADULT; AGE; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG MONITORING; ELECTRONICS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; URBAN POPULATION;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ELECTRONICS, MEDICAL; FEMALE; HUMANS; HYPERTENSION; INDOLES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISK; SEX FACTORS; SMOKING; SOCIOECONOMIC FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032947977     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00274-X     Document Type: Article

References (25)

1. Lee JY, Kusek JW, Greene PG, et al: Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) pilot study. Am J Hypertens 1996;9:719-725.
2. Pullar T, Kumar S, Tindall H, et al: Time to stop counting the tablets? Clin Pharmacol Ther 1989;46:163-168.
3. Kruse W, Weber E: Dynamics of drug regimen compliance. Its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990;38:561-565.
4. Mallion JM, Dutrey-Dupagne C, Vaur L, et al: Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension. J Hypertens 1996;14:137-144.
5. Wiseman LR, McTavish D: Trandolapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994;48:71-90.
6. Mallion JM, Meilhac B, Tremel F, et al: Use of a microprocessor-equipped tablet box in monitoring compliance with antihypertensive treatment. J Cardiovasc Pharmacol 1992;19(suppl 2):S41-S48.
7. Rudd P, Ahmed S, Zachary AS, et al: Improved compliance measures: application in an ambulatory hypertensive trial. Clin Pharmacol Ther 1990;48:676-685.
8. Detry JMR, Black P, De Backer G, et al: The Belgian collaborative study group. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur J Clin Pharmacol 1995;47:447-481.
9. Oddson OH, Bass MJ, Donner A, et al: Behaviour pattern A and compliance with antihypertensive treatment. Acta Med Scand 1985;693(suppl):97-101.
10. Stewart M: The validity of an interview to assess a patient's drug taking. Am J Prev Med 1987;3:95-100.
11. McClellan WM, Dallas Hall WD, Brogan D, et al: Continuity of care in hypertension. Arch Intern Med 1988; 148:525-528.
12. Briggs WA, Lowenthal DT, Cirksena WJ, et al: Propranolol in hypertensive dialysis patients: efficacy and compliance. Clin Pharmacol Ther 1976;18:606-612.
13. Eisen SA, Miller DK, Woodword RS, et al: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-1884.
14. Fujii J, Seki A: Compliance and compliance-improving strategies in hypertension: the Japanese experience. J Hypertens 1985;3(suppl 1):19-22.
15. Cramer JA, Mattson RH, Prevey ML, et al: How often is medication taken as prescribed? A novel assessment technique. J Am Med Assoc 1979;261:3273-3277.
16. Waeber B, Erne P, Saxenhofer H, et al: Use of drug with more than a twenty-four-hour duration of action. J Hypertens 1994;12(suppl 3):S67-S71.
17. Poncelet P, Genes N, Vaur L, et al: Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimens. J Hypertens 1997;15(suppl 4):S3-S4.
18. Juncos LI. Patient compliance and angiotensin converting enzyme inhibitors in hypertension. J Cardiovasc Pharmacol 1990;15(suppl 3):S22-S25.
19. Sackett DL, Haynes RB, Gibson ES, et al: Patient compliance with antihypertensive regimens. Patient's Counsel Health Educ 1978;1:18-21.
20. Cesarone MR, De Sanctis MT, Laurora G, et al: Effects of trandolapril on 24-h ambulatory blood pressure in patients with mild to moderate hypertension. J Cardiovase Pharmacol 1994;23(suppl 4):S65-S72.
21. Vaur L, Dutrey-Dupagne C, Boussac J, et al: Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 1995;26:127-131.
22. Girvin B, Johnston GD: The implications of non compliance with antihypertensive medication. Drugs 1996; 52:186-195.
23. Elliot WJ: Compliance strategies. Curr Opin Nephrol Hypertens 1994;3:271-278.
24. Guerrero D, Rudd P, Bryant-Kosling C, et al: Antihypertensive medication-taking: investigation of a simple regimen. Am J Hypertens 1993;6:586-592.
25. Meredith PA: Therapeutic implications of drug "holidays." Eur Heart J 1996;17(suppl A):21-24.